Trial
NCT02343549
A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Wake Forest University Health Sciences
Collaborators
NovoCure Ltd.
Condition
Cancer of Brain and Nervous System
Intervention
NovoTTF100A
Why stopped
closed to accrual due to low accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-11-03